ARCHIVES

Graalman Objects To Criticism On Contract Competition

This article is from The Cancer Letter archive.

Vol. 03 No. 16 | April 22, 1977

Download PDF Visit The Full Archive

Related Articles

First NCI Director To Resign Due To Presidential Election?

December 15, 2000

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

FDA Ceases Exclusion Of Women From Early Drug Studies

May 7, 1993

FASEB Urges Better Funding, Management Of Biomedical Research

February 23, 1996

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

NCI director says rules hurt retention, recruitment, cites Liotta’s departure.

April 8, 2005